This bill mandates that medical care providers review FDA medication guides with the parent, guardian, or state-designated caregiver before prescribing psychotropic drugs to minors under Medicaid. It introduces a new section, RSA 167:3-n, which defines "psychotropic drugs" and outlines the responsibilities of medical care providers. Specifically, providers must provide a physical copy of the FDA medication guide, explain the risks and potential side effects, and obtain written informed consent from the parent or guardian confirming their understanding of the medication's risks.

Additionally, the bill stipulates that non-compliance with these requirements may result in penalties, including suspension of Medicaid reimbursements and reporting to the appropriate governing board. The bill does not allocate funding or authorize new positions but is expected to incur significant costs for the state, estimated between $1 million to $2.5 million annually, due to the increased administrative burden on the Department of Health and Human Services. The act is set to take effect on April 1, 2026.